http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
-
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
-
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
-
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
-
SpringWorks Therapeutics (SWTX) Reports Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO
-
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncolo
-
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
-
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
-
SpringWorks Therapeutics Inc. (SWTX) Granted FDA Priority Review to NDA for Mirdametinib
-
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
-
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Inc. (SWTX) Appoints Dr. Martin Mackay to its Board of Directors
-
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
-
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
-
SpringWorks Therapeutics Inc. (SWTX) Completes Submission of NDA for Mirdametinib
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
-
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
-
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
-
SpringWorks Therapeutics (SWTX) Reports Rolling Submission of New Drug Application for Mirdametinib
-
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks Therapeutics (SWTX) Granted EMA Validation of Marketing Authorization Application of Nirogacestat
-
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
-
SpringWorks Therapeutics (SWTX) Announces FDA Approval of OGSIVEO
-
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
-
SpringWorks Therapeutics (SWTX) Reports Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
-
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
-
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
-
SpringWorks Therapeutics (SWTX) Appoints Tai-An Lin as Chief Scientific Officer
-
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
-
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
-
SpringWorks Therapeutics Inc. (SWTX) Announces PDUFA Date Extension for Nirogacestat NDA
-
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
-
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
-
SpringWorks Therapeutics Inc. (SWTX) achieved full enrollment in its Phase 2 trial evaluating nirogacestat
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
-
SpringWorks Therapeutics Inc. (SWTX) Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat
-
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
